Cambrex — Merger or Acquisition (November 2018)
10 slides from Cambrex's merger presentation, Nov 20, 2018
Slide 1: Cambrex to Acquire Avista Pharma Solutions
Cambrex to Acquire Avista Pharma Solutions November 20, 2018 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation regarding the acquisition of Avista Pharma Solutions (“Avista”) and expected benefits therefrom (including revenue and earnings expectations and the expected accretive effect of the transaction in 2019), future financial and operating result
Slide 3: Transaction Overview
Transaction Overview $252 million total cash consideration To be funded with balance sheet cash and borrowings under existing senior credit facility (expanded under accordion feature) Avista 2018 organic growth rate expected to be ~40% vs 2017 Full year 2018 Revenue expected to be ~$65 million, brin
Slide 4: Avista Overview
Avista Pharma Solutions Overview Offers a full suite of comprehensive small molecule services Process chemistry, formulation development, API & drug product manufacturing Analytical development and testing, stability storage and testing Solid state chemistry Center of excellence and leading provider
Slide 5: Strategic Rationale
Strategic Rationale Performs early stage services for a large number of projects each year, some of which will advance and eventually require Cambrex’s larger scale API and finished dosage form assets Rapidly growing customer base, creating a large and expanding pool of customers to cross-sell a bro
Slide 6: Strengthens Pipeline, Broadens Capabilities, Adds New Growth Platforms
Strengthens Pipeline, Broadens Capabilities, Adds New Growth Platforms Drug Development Commercialization Clinical Phase I Clinical Phase II Clinical Phase III Launch Phase IV Generics Preclinical Development File IND File NDA Clinical Stage (High Point, NC) Late Stage (Charles City, IA) Late Stage
Slide 7: Further Enhances Position in Both Segments of the Small Molecule CDMO Market
Avista provides early stage development services to both the API and finished dosage form markets, both large growing markets with increasing levels of outsourcing penetration Further Enhances Position in Both Segments of the Small Molecule CDMO Market [1] Source: Cambrex estimates, Wall Street equi
Slide 8: Cambrex and Avista – At-a-Glance
Edinburgh, UK Leading provider of solid state science and crystallization development services Formerly Solid Form Solutions Longmont (CO), USA Offers CMC from patent to patient from a single facility Drug substance and drug product manufacturing and packaging Cambrex and Avista – At-a-Glance Cambre
Slide 9: Summary
Enhances early phase capabilities across small molecule drug substance and drug product markets Strengthens pipeline, broadens capabilities, adds new growth platforms Provides access to a large number of new customers Further enhances position in both segments of the small molecule CDMO Market Adds
Slide 10: Cambrex to Acquire Avista Pharma Solutions
Cambrex to Acquire Avista Pharma Solutions November 20, 2018